BECN1 and colorectal cancer: CPUK02 (1,6,8,10,16,32 and 64 μM in two cell lines) treatment inhibited the UPR and modulated autophagy by decreasing Beclin-1 and increasing P62 and LC3βII mRNA levels in colorectal cancer cells.